CY1118512T1 - Παραγωγα 3,4-διϋδροπυρρολο[1,2-α]πυραζινο-2,8(1η)-δικαρβοξαμιδιου, παρασκευη αυτων και θεραπευτικη χρηση αυτων - Google Patents
Παραγωγα 3,4-διϋδροπυρρολο[1,2-α]πυραζινο-2,8(1η)-δικαρβοξαμιδιου, παρασκευη αυτων και θεραπευτικη χρηση αυτωνInfo
- Publication number
- CY1118512T1 CY1118512T1 CY20161101179T CY161101179T CY1118512T1 CY 1118512 T1 CY1118512 T1 CY 1118512T1 CY 20161101179 T CY20161101179 T CY 20161101179T CY 161101179 T CY161101179 T CY 161101179T CY 1118512 T1 CY1118512 T1 CY 1118512T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alkyl
- cycloalkyl
- group
- therapeutic use
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Ενώσεις οι οποίες αντιστοιχούν στον γενικό τύπο (I) όπου το R2 αντιπροσωπεύει μια ομάδα C1-10-αλκυλ, C3-10- κυκλοαλκυλ, C3-7-κυκλοαλκυλ-C1-6-αλκυλ, C1-6-αλκυλ-C3-7-κυκλοαλκυλ, C3-7-κυκλοαλκυλ-C3-7-κυκλοαλκυλ, C1-6-αλκυλθειο-C-1-10-αλκυλ, C1-6-αλκοξυ-C1-10-αλκυλ, υδροξυ-C1-10-αλκυλ, υδροξυ-C1-6-αλκυλ-C3-7-κυκλοαλκυλ-C1-6αλκυλ, υδροξυ-C3-10-κυκλοαλκυλ, C1-10-φθοροαλκυλ ή C3-10-φθοροκυκλοαλκυλ, μια προαιρετικώς υποκατεστημένη ετεροκυκλική ομάδα, μια ομάδα C1-10-αλκυλ υποκατεστημένη με μια προαιρετικώς υποκατεστημένη ετεροκυκλική ομάδα, το Xe αντιπροσωπεύει μια ομάδα η οποία επιλέγεται από άτομα υδρογόνου, φθορίου, χλωρίου και βρωμίου ή μια ομάδα C1-6-αλκυλ, C3-7-κυκλοαλκυλ, C3-7- κυκλοαλκυλ-C1-6-αλκυλ, C1-6-φθοροαλκυλ ή κυανό, και το R7 αντιπροσωπεύει μια αρυλ ομάδα όπως φαινυλ ή ναφθυλ, προαιρετικώς υποκατεστημένη με έναν ή περισσότερους υποκαταστάτες, στη μορφή της βάσης ή ενός άλατος προσθήκης οξέος. Θεραπευτική χρήση.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1054372A FR2960876B1 (fr) | 2010-06-03 | 2010-06-03 | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
| PCT/IB2011/001594 WO2011161537A2 (en) | 2010-06-03 | 2011-06-01 | 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118512T1 true CY1118512T1 (el) | 2017-07-12 |
Family
ID=42697541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101179T CY1118512T1 (el) | 2010-06-03 | 2016-11-16 | Παραγωγα 3,4-διϋδροπυρρολο[1,2-α]πυραζινο-2,8(1η)-δικαρβοξαμιδιου, παρασκευη αυτων και θεραπευτικη χρηση αυτων |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8791119B2 (el) |
| EP (1) | EP2588480B1 (el) |
| JP (1) | JP5995841B2 (el) |
| KR (1) | KR20130113928A (el) |
| CN (1) | CN103168041B (el) |
| AR (1) | AR081832A1 (el) |
| AU (1) | AU2011268651B2 (el) |
| BR (1) | BR112012030697A2 (el) |
| CA (1) | CA2801154C (el) |
| CL (1) | CL2012003360A1 (el) |
| CO (1) | CO6602113A2 (el) |
| CR (1) | CR20120595A (el) |
| CY (1) | CY1118512T1 (el) |
| DK (1) | DK2588480T3 (el) |
| DO (1) | DOP2012000296A (el) |
| EA (1) | EA201291364A1 (el) |
| EC (1) | ECSP12012322A (el) |
| ES (1) | ES2603420T3 (el) |
| FR (1) | FR2960876B1 (el) |
| GT (1) | GT201200319A (el) |
| HR (1) | HRP20161494T1 (el) |
| HU (1) | HUE030650T2 (el) |
| IL (1) | IL223364A (el) |
| LT (1) | LT2588480T (el) |
| MA (1) | MA34360B1 (el) |
| MX (1) | MX2012014084A (el) |
| NI (1) | NI201200176A (el) |
| NZ (1) | NZ603947A (el) |
| PE (1) | PE20130259A1 (el) |
| PL (1) | PL2588480T3 (el) |
| PT (1) | PT2588480T (el) |
| SG (1) | SG186143A1 (el) |
| SI (1) | SI2588480T1 (el) |
| TN (1) | TN2012000520A1 (el) |
| TW (1) | TWI487707B (el) |
| UY (1) | UY33428A (el) |
| WO (1) | WO2011161537A2 (el) |
| ZA (1) | ZA201209071B (el) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
| AR098414A1 (es) * | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
| JP6307989B2 (ja) * | 2014-04-02 | 2018-04-11 | 住友化学株式会社 | 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法 |
| EP3610040A1 (en) | 2017-04-12 | 2020-02-19 | H. Hoffnabb-La Roche Ag | A method for sequencing reaction with tagged nucleoside obtained via pictet spengler reaction |
| KR20200032702A (ko) * | 2017-07-27 | 2020-03-26 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피페라진 헤테로아릴 유도체, 그 제조 방법 및 의약에서 이의 용도 |
| TW202412758A (zh) * | 2022-06-29 | 2024-04-01 | 香港商英矽智能科技知識產權有限公司 | Fgfr2與fgfr3抑制劑及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1150991B1 (en) | 1999-02-01 | 2004-04-07 | University of Virginia Patent Foundation | Compositions for treating inflammatory response |
| MXPA04002243A (es) * | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
| GB0202015D0 (en) * | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
| US7402672B2 (en) | 2003-12-11 | 2008-07-22 | Aventis Pharmaceuticals Inc. | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon |
| GB0328900D0 (en) | 2003-12-12 | 2004-01-14 | Glaxo Group Ltd | Novel compounds |
| WO2008147713A1 (en) * | 2007-05-24 | 2008-12-04 | The Regents Of The University Of California | Wnt signaling inhibitors, and methods for making and using them |
| CA2694288A1 (fr) * | 2007-07-27 | 2009-04-09 | Sanofi-Aventis | Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamides, leur preparation et leur application en therapeutique |
| CA2712265A1 (en) * | 2008-01-17 | 2009-07-23 | Gruenenthal Gmbh | Substituted sulfonamide derivatives |
| US20090192147A1 (en) * | 2008-01-30 | 2009-07-30 | Wyeth | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
| FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
-
2010
- 2010-06-03 FR FR1054372A patent/FR2960876B1/fr not_active Expired - Fee Related
-
2011
- 2011-06-01 KR KR1020127031424A patent/KR20130113928A/ko active Search and Examination
- 2011-06-01 SG SG2012088795A patent/SG186143A1/en unknown
- 2011-06-01 PL PL11781590T patent/PL2588480T3/pl unknown
- 2011-06-01 MX MX2012014084A patent/MX2012014084A/es active IP Right Grant
- 2011-06-01 MA MA35524A patent/MA34360B1/fr unknown
- 2011-06-01 EA EA201291364A patent/EA201291364A1/ru unknown
- 2011-06-01 LT LTEP11781590.2T patent/LT2588480T/lt unknown
- 2011-06-01 AU AU2011268651A patent/AU2011268651B2/en not_active Ceased
- 2011-06-01 SI SI201131022A patent/SI2588480T1/sl unknown
- 2011-06-01 WO PCT/IB2011/001594 patent/WO2011161537A2/en active Application Filing
- 2011-06-01 PE PE2012002257A patent/PE20130259A1/es not_active Application Discontinuation
- 2011-06-01 NZ NZ603947A patent/NZ603947A/en not_active IP Right Cessation
- 2011-06-01 BR BR112012030697A patent/BR112012030697A2/pt not_active IP Right Cessation
- 2011-06-01 PT PT117815902T patent/PT2588480T/pt unknown
- 2011-06-01 EP EP11781590.2A patent/EP2588480B1/en active Active
- 2011-06-01 JP JP2013513006A patent/JP5995841B2/ja not_active Expired - Fee Related
- 2011-06-01 CN CN201180038277.8A patent/CN103168041B/zh not_active Expired - Fee Related
- 2011-06-01 CA CA2801154A patent/CA2801154C/en not_active Expired - Fee Related
- 2011-06-01 DK DK11781590.2T patent/DK2588480T3/en active
- 2011-06-01 HU HUE11781590A patent/HUE030650T2/en unknown
- 2011-06-01 ES ES11781590.2T patent/ES2603420T3/es active Active
- 2011-06-02 AR ARP110101901A patent/AR081832A1/es not_active Application Discontinuation
- 2011-06-03 UY UY0001033428A patent/UY33428A/es unknown
- 2011-06-03 TW TW100119696A patent/TWI487707B/zh not_active IP Right Cessation
-
2012
- 2012-10-31 TN TNP2012000520A patent/TN2012000520A1/en unknown
- 2012-11-22 DO DO2012000296A patent/DOP2012000296A/es unknown
- 2012-11-26 CR CR20120595A patent/CR20120595A/es unknown
- 2012-11-27 GT GT201200319A patent/GT201200319A/es unknown
- 2012-11-29 IL IL223364A patent/IL223364A/en not_active IP Right Cessation
- 2012-11-29 US US13/688,916 patent/US8791119B2/en not_active Expired - Fee Related
- 2012-11-30 CL CL2012003360A patent/CL2012003360A1/es unknown
- 2012-11-30 ZA ZA2012/09071A patent/ZA201209071B/en unknown
- 2012-11-30 NI NI201200176A patent/NI201200176A/es unknown
- 2012-12-03 EC ECSP12012322 patent/ECSP12012322A/es unknown
- 2012-12-03 CO CO12218640A patent/CO6602113A2/es active IP Right Grant
-
2014
- 2014-07-23 US US14/339,112 patent/US9233965B2/en not_active Expired - Fee Related
-
2016
- 2016-11-11 HR HRP20161494TT patent/HRP20161494T1/hr unknown
- 2016-11-16 CY CY20161101179T patent/CY1118512T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118512T1 (el) | Παραγωγα 3,4-διϋδροπυρρολο[1,2-α]πυραζινο-2,8(1η)-δικαρβοξαμιδιου, παρασκευη αυτων και θεραπευτικη χρηση αυτων | |
| CY1123626T1 (el) | Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης | |
| CY1119534T1 (el) | Παραγωγα φωσφορου ως αναστολεις κινασης | |
| CY1123407T1 (el) | Σταθερες υδατικες φαρμακοτεχνικες μορφες της αδαλιμουμαμπης | |
| CY1117374T1 (el) | Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων | |
| CY1119049T1 (el) | Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια | |
| CY1118129T1 (el) | 5-αλκυνυλ-πυριμιδινες | |
| CY1117846T1 (el) | 1-(3,3-ΔΙΜΕΘΥΛΟΒΟΥΤΥΛΟ)-3-(2-ΦΘΟΡΟ-4-ΜΕΘΥΛΟ-5-(7-ΜΕΘΥΛΟ-2-(ΜΕΘΥΛΑΜΙΝΟ)ΠΥΡΙΔΟ-[2,3-d]ΠΥΡΙΜΙΔΙΝ-6-ΥΛΟ)ΦΑΙΝΥΛ)ΟΥΡΙΑ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΚΙΝΑΣΗΣ RAF ΣΤΗΝ ΑΓΩΓΗ ΕΝΑΝΤΙ ΤΟΥ ΚΑΡΚΙΝΟΥ | |
| CY1110232T1 (el) | Παραγωγα 2-αρυλ-6-φαινυλ-ιμιδαζο[1,2-α]πυριδιν, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη | |
| CY1114539T1 (el) | Η χρησιμοτητα των ιμιδαζοπυριδαζινοκαρβονιτριλιων ως αναστολεων κινασων | |
| NI201300103A (es) | INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [ 2, 3-d] PIRIMIDINA TROPOMIOSINA | |
| CY1116315T1 (el) | Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3 | |
| CO6950483A2 (es) | 5,7-imidazo[1,2-c]pirimidinas sustituidas | |
| ECSP088145A (es) | Derivados bicíclicos como inhibidores de la cinasa p38 | |
| CY1113549T1 (el) | Πολυυποκατεστημενα παραγωγα των 2-αρυλο-6-φαινυλ-ιμιδαζο[1,2-α]πυριδινων, η παρασκευη τους και η θεραπευτικη εφαρμογη τους | |
| HN2010000432A (es) | Derivados de 2-alquiltio-2-quinoliniloxi-acetamida como fungicidas | |
| NI201200191A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
| MX2015003538A (es) | Derivados de 3-fenilisoxazolina con accion herbicida. | |
| CU20110078A7 (es) | Compuestos de carbazol | |
| ECSP11011206A (es) | Nuevos herbicidas. | |
| UY32553A (es) | Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos | |
| NI201100139A (es) | Microbiocidas nuevos. | |
| ECSP12011678A (es) | Metilpirrolopirimidincarboxamidas | |
| UY32280A (es) | DERIVADOS DE 6-CICLOAMINO-3-(1H-PIRROLO[2,3-b]PIRIDIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACIÓN Y SU APLICACIÓN EN TERAPÉUTICA | |
| UY32348A (es) | DERIVADOS DE 6-CICLOAMINO-2-TIENIL-3-(PIRIDIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA Y 6-CICLOAMINO-2-FURANIL-3-(PIRIDIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACIÓN Y SU APLICACIÓN EN TERAPEUTICA |